Korsana Biosciences, Inc. (KRSA) financials: revenue, earnings and cash flow
Fiscal 2018–2025 · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$4M, a net margin of -170.1%; the best year in this period was 2024 with -$3M.
The diluted share count rose 132% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | $0 | $297000 | $4M | $2M | $5M | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5M | -$4M | -$13M | -$19M | -$55M | -$81M | -$125M | -$115M |
| Net income | -$4M | -$3M | -$5M | -$44M | -$52M | -$78M | -$123M | -$115M |
| EPS (diluted) | $-0.07 | $-0.08 | $-0.15 | $-1.35 | $-1.76 | $-3.41 | $-5.99 | $-0.01 |
| R&D | $959000 | $286000 | $2M | $6M | $38M | $56M | $95M | $88M |
| Revenue growth | +3.7% | — | −100.0% | −92.5% | +71.7% | −49.1% | — | — |
Cash flow
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3M | -$4M | -$21M | -$41M | -$37M | -$72M | -$102M | -$98M |
| Capital spending | — | — | — | $0 | -$7000 | -$2M | -$7M | -$3M |
| Free cash flow | — | — | — | -$41M | -$37M | -$74M | -$109M | -$101M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $441000 | $625000 | $1M | $6M | $10M | $15M | $20M | $12M |
Balance sheet
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash | $3M | $3M | $8M | $13M | $54M | $54M | $95M | — |
| Debt | — | — | — | $4M | $4M | $46M | $74M | — |
| Equity | $9M | $9M | $11M | $10M | $48M | $59M | $98M | -$10M |
| Total assets | $10M | $10M | $13M | $18M | $59M | $115M | $186M | $7M |
| Shares (diluted) | 48M | 38M | 35M | 33M | 29M | 23M | 21M | 21M |
Margins and returns
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -239.8% | -181.4% | — | -6242.4% | -1400.2% | -3539.4% | -2774.3% | — |
| Net margin | -170.1% | -152.8% | — | -14841.1% | -1310.2% | -3388.6% | -2729.3% | — |
| FCF margin | — | — | — | -13673.7% | -926.5% | -3223.6% | -2420.8% | — |
| ROIC | -54.7% | -41.0% | -114.7% | -132.9% | -106.7% | -77.2% | -72.8% | — |
| ROE | -38.8% | -34.5% | -46.6% | -421.7% | -107.0% | -130.8% | -125.9% | 1103.4% |
Frequently asked questions
What is Korsana Biosciences’s annual revenue?
$2M in fiscal 2025.
How much profit does Korsana Biosciences make?
Net income was -$4M in fiscal 2025 (net margin -170.1%).
Is Korsana Biosciences’s revenue growing?
Yes: revenue rose 3.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.